Wedbush Starts Inhibitex (INHX) at Outperform; Possible Partnership or Acquisition Candidate
Tweet
Share
E-mailGet Alerts INHX Hot Sheet
Price: $26.00 --0%
Rating Summary:
5 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 25
Rating Summary:
5 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 25
Join SI Premium – FREE
Wedbush initiates coverage on Inhibitex (NASDAQ: INHX) with an Outperform. PT $9.00.
Wedbush analyst says, "Our thesis centers on the conviction that Inhibitex could attract a high profile partnership or be an acquisition candidate. INHX is developing one of only two later-clinical stage HCV drug candidates in the sought-after class of nucleotides which is not owned by or partnered to big pharma."
For more ratings news on Inhibitex click here and for the rating history of Inhibitex click here.
Shares of Inhibitex closed at $4.27 yesterday.
Wedbush analyst says, "Our thesis centers on the conviction that Inhibitex could attract a high profile partnership or be an acquisition candidate. INHX is developing one of only two later-clinical stage HCV drug candidates in the sought-after class of nucleotides which is not owned by or partnered to big pharma."
For more ratings news on Inhibitex click here and for the rating history of Inhibitex click here.
Shares of Inhibitex closed at $4.27 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Starts Centrus Energy Corp. (LEU) at Equalweight
- Macquarie Starts Sunway Construction (SCGB:MK) at Neutral
- Truist Securities Assumes Corcept Therapeutics (CORT) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
